6th Annual Biologics Manufacturing Asia 2019

The biologics manufacturing industry has undergone several changes over the past few years starting from the development of better expression systems to modular and flexible manufacturing facilities including the emergence and use of disposables. However, there is a need for higher productivity when it comes to upstream, need for efficient process development and cost-effective and alternative techniques when it comes to downstream processing. This apart, the industry also handles specific issues on designing facilities for flexibility and in the wake of multiple products.

The biologics industry in Asia- Pacific is estimated to be the fastest growing market in the world, for instance, Asia- Pacific accounts for alone 30% of the global biosimilar market. Low manufacturing costs and the presence of high-skilled workers at low costs are also factors that make Asia- Pacific a lucrative destination for the biologics market.

The key drivers driving the growth of the biologics industry in Asia are new- cell culture techniques, fast-track GMP facilities, flexible manufacturing facilities using disposables, attempts for continuous manufacturing, combining modular facilities and single-use and other advances in the downstream processing of biologics. However, the factors hindering the growth of the biopharmaceutical industry mainly are from the bioprocessing side including high-manufacturing complexities, expensive purification processes and other challenges across the bioprocessing value chain.